ストックスクリーナーアプリを入手
3.26
2.70%
-0.02
アフターアワーズ：
3.26
前日終値:
$3.28
開ける：
$3.27
24時間の取引高:
10,738
Relative Volume:
0.34
時価総額：
$7.47M
収益：
$3.19M
当期純損益:
$-2.23M
株価収益率:
-2.6519
EPS:
-1.2293
ネットキャッシュフロー:
$-1.82M
1週間 パフォーマンス:
+3.28%
1か月 パフォーマンス:
+14.72%
6か月 パフォーマンス:
+46.40%
1年 パフォーマンス:
+11.59%
1日の値動き範囲:
$3.18
$3.27
1週間の範囲:
$3.06
$3.30
52週間の値動き範囲:
$1.90
$13.93
Xenetic Biosciences Inc Stock (XBIO) Company Profile
名前
Xenetic Biosciences Inc
セクター
電話
781-778-7720
住所
945 CONCORD ST., FRAMINGHAM, MA
Compare XBIO vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XBIO
Xenetic Biosciences Inc
|
3.26 | 7.51M | 3.19M | -2.23M | -1.82M | -1.2293 |
VRTX
Vertex Pharmaceuticals Inc
|
515.55 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.93 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
987.84 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.00 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.51 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-01-08 | 開始されました | Maxim Group | Buy |
Xenetic Biosciences Inc (XBIO) 最新ニュース
Xenetic Biosciences Q2 royalty revenue rises on Takeda sublicense - TradingView
Xenetic Biosciences reports Q2 2026: $0.7M royalty revenue, $0.9M quarterly net loss - TradingView
Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform - Yahoo Finance
Xenetic Biosciences: Q2 Earnings Snapshot - marketscreener.com
Xenetic Biosciences, Inc. 2026: Revenue $660.6K, EPS ($0.41) — 10-Q Summary - TradingView
Xenetic Biosciences (XBIO) Rises 3.31% to $2.81, Approaching Key Resistance at $2.95TWAP Entry - dars.gov.et
Xenetic Biosciences Inc. (XBIO) Q2 2025 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline - dars.gov.et
Xenetic Biosciences Inc. (XBIO) Q2 2025 Earnings: EPS Beat Driven by Cost Discipline Amid Clinical-Stage Operations - dars.gov.et
Xenetic Biosciences Inc (XBIO) Financial Health: Profitability & Balance Sheet Analysis - tradingkey.com
Xenetic Biosciences Inc (XBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Xenetic Biosciences Inc (XBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
XBIO|Xenetic Biosciences Inc|Price:2.640|Chg%:-0.085 - TradingKey
Xenetic Biosciences Inc (XBIO) Cash Flow - TradingKey
Xenetic Biosciences Inc (XBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Xenetic Biosciences Inc (XBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Xenetic Biosciences Inc (XBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
XBIO Q2 2025 Earnings: Narrower-Than-Expected Loss Drives Stock HigherFinal Results - dars.gov.et
Xenetic Biosciences (XBIO) Slides 1% as Shares Approach Key SupportInvestment Factor - po-news-eg.net
Xenetic Biosciences (XBIO) Rises 3.58% as Biotech Stock Nears Key ResistancePut Spread Alert - dars.gov.et
Number of shareholders of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Price to book forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Enterprise value to revenue forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Price to earnings forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Enterprise value to EBITDA forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Price to sales forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Enterprise value to EBIT forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Xenetic Biosciences (XBIO) Surges 6.14% as Stock Tests Key Resistance at $3.09Large Cap Trends - dars.gov.et
XBIOXenetic Biosciences Inc Latest SEC Filings - Finviz
Xenetic Biosciences, Inc. Actuals & Estimates (NASDAQ:XBIO) - TradingView
Xenetic Biosciences Inc (XBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Xenetic Biosciences Inc (XBIO) Institutional Confidence - TradingKey
Xenetic Biosciences Inc (XBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Xenetic Biosciences (XBIO) Gains 6.7% – Bullish Breakout Within Tight RangeBreakout Stock Alerts - newsline.com
Xenetic Biosciences Inc. (XBIO) Q2 2025 Earnings: Narrowed Loss Beats Expectations, Pipeline Progress KeyRevenue Surprise History - dars.gov.et
XBIO Q2 2025 Earnings: EPS Surpasses Estimates Despite No RevenueLong-Term Guidance - dars.gov.et
XBIO Q2 2025 Earnings: Narrower Loss Beats Estimates, Yet Stock Slips on No Revenue ProgressAnalyst Coverage Count - dars.gov.et
Xenetic Biosciences (XBIO) Secures Approval for Clinical Study i - GuruFocus
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma - ACCESS Newswire
Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates - MSN
Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival - BioSpace
Xenetic presents preclinical data on DNase I with CAR-T therapy - Investing.com Nigeria
Xenetic (XBIO) Reveals Promising Preclinical Results for CAR-T Therapy - GuruFocus
Xenetic presents preclinical data on DNase I with CAR-T therapy By Investing.com - Investing.com South Africa
Xenetic Biosciences, Inc.: Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival - FinanzNachrichten.de
After CAR-T failure, DNase I tied to tumor decline in pediatric lymphoma case - Stock Titan
Michael Liu and MJL Manager LLC report stakes in Xenetic Biosciences (NASDAQ: XBIO) - Stock Titan
XBIO Q2 2025 Earnings: Narrowed Loss Exceeds Expectations as Pipeline AdvancesProfit Inflection Point - dars.gov.et
Xenetic Biosciences Inc (XBIO) 財務データ
収益
当期純利益
現金流量
EPS
2.20%
0.07%
大文字化:
|
ボリューム (24 時間):